Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has a ‘Buy’ or equivalent rating from 82% of the analysts covering the stock. While the price target ranges from $17 to $45, the one-year median price target of $33 translates to an upside potential of over 300%.

On December 19, Scott Bizily, the CLO of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), offloaded 1,635 shares of the company’s stock, worth a total of approximately $17,821.

Earlier on December 17, 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) reported positive interim clinical data from its 4D-710 Phase 1 AEROW clinical trial targeting cystic fibrosis lung disease, according to TheFly. Since the previous update, the higher-dose cohorts have demonstrated no new pulmonary or other safety events, with up to 3.5 years of follow-up. 4D-710-related unfavorable events were observed to be mild and resolvable within 2 months in lower-dose cohorts, with no severe 4D-710-related adverse events.

Airway biopsy and brushing outcomes showed stable and dose-dependent CFTR transgene RNA levels at or above physiologically relevant levels compared with non-CF control samples. In the 2.5E14 vg dose cohort, the results were totally in line with the target expression profile, exhibiting evidence of meaningful activity across all endpoints, particularly ppFEV1 and LCI2.5.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a California-based late-stage biotechnology company specializing in adeno-associated virus vectors. Founded in 2013, the company operates through Therapeutic Vector Evolution, a proprietary synthetic vector discovery platform.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.